MYPPPY variants of CTL A4 and uses thereof
US5773253A · kind A · utility
95Cited by
4References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 21, 1995 |
| Grant date | Jun 30, 1998 |
| Priority date | — |
| Expiry date | Jul 21, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides CTLA4 mutant molecules as ligands for the B7 antigen. Methods are provided for expressing CTLA4 mutant molecules as soluble, functional molecules, for preparing CTLA4 mutant fusion proteins, and for using these soluble molecules to regulate T cell interactions and immune responses mediated by such interactions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.